

Amended Claims for PCT Application No. PCT/EP00/02467

Claims:

- svb
B' 1
1. An immunogenic composition comprising at least one *Streptococcus pneumoniae* polysaccharide antigen, at least one *Streptococcus pneumoniae* protein antigen or immunologically functional equivalent thereof, and an adjuvant which is a preferential inducer of a TH1 response.
2. The immunogenic composition of claim 1, wherein the protein antigen is an outer surface protein or a secreted protein of *Streptococcus pneumoniae* or immunologically functional equivalents thereof.
3. The immunogenic composition of claims 1 or 2, wherein the protein antigen is a toxin, adhesin or lipoprotein of *Streptococcus pneumoniae* or immunologically functional equivalents thereof.
- Sub
2
4. The immunogenic composition of claims 1-3, wherein the protein antigen or immunologically functional equivalent thereof is selected from the group: pneumolysin, PspA or transmembrane deletion variants thereof, PspC or transmembrane deletion variants thereof, PsaA or transmembrane deletion variants thereof, glyceraldehyde-3-phosphate dehydrogenase, and CbpA or transmembrane deletion variants thereof.
5. The immunogenic composition of claims 1-4, wherein the polysaccharide antigen is presented in the form of a polysaccharide-protein carrier conjugate.
- svb
B' 1
6. The immunogenic composition of claim 5, wherein the carrier protein is selected from the group consisting of: Diphtheria toxoid, Tetanus toxoid, CRM197, Keyhole Limpet Haemocyanin (KLH), protein derivative of Tuberculin (PPD), and protein D from *H. influenzae*.

7. An immunogenic composition as claimed in any of claims 1 to 6 which comprises at least four pneumococcal polysaccharide antigens from different serotypes.

8. An immunogenic composition as claimed in any of claims 1 to 7, wherein the adjuvant comprises at least one of the following: 3D-MPL, a saponin immunostimulant, or an immunostimulatory CpG oligonucleotide.

9. An immunogenic composition as claimed in claim 8, wherein the adjuvant comprises a carrier selected from the group comprising: an oil in water emulsion, liposomes, and an aluminium salt.

10. An immunogenic composition as claimed in any one of claims 1-9 for use as a medicament.

11. A vaccine comprising the immunogenic composition of claims 1-9.

12. A method of preventing or ameliorating *Streptococcus pneumoniae* infection in a patient over 55 years, comprising administering an effective amount of a vaccine comprising a *Streptococcus pneumoniae* polysaccharide, at least one *Streptococcus pneumoniae* protein, and a TH1 inducing adjuvant.

13. Use of a pneumococcal polysaccharide antigen in combination with a *Streptococcus pneumoniae* protein antigen, and a TH1 inducing adjuvant, in the manufacture of a medicament for the prevention of pneumonia in patients over 55 years.